TABLE 1.
Susceptibilities of 43 clinical isolates of E. coli O157 and 56 clinical isolates of non-O157 E. coli to antimicrobial agentsa
| Antimicrobial agent | MIC (μg/ml)
|
||
|---|---|---|---|
| Range (μg/ml) | 50% | 90% | |
| Ampicillin | 2 to >128 | 2 | 4 |
| Arbekacin | 0.5 to 1 | 1 | 1 |
| Cefaclor | 2 to 4 | 2 | 2 |
| Cefdinir | ≤0.13 to 0.5 | 0.25 | 0.25 |
| Cefditoren | ≤0.13 to 0.5 | 0.25 | 0.25 |
| Cefmetazole | 0.25 to 1 | 0.50 | 0.50 |
| Cefotetiam | ≤0.13 | ≤0.13 | ≤0.13 |
| Cefpodoxime | 0.25 to 0.5 | 0.50 | 0.50 |
| Ceftazidime | ≤0.13 to 0.25 | ≤0.13 | ≤0.13 |
| Cefteram | ≤0.13 to 0.25 | 0.25 | 0.25 |
| Ciprofloxacin | ≤0.13 | ≤0.13 | ≤0.13 |
| Clavulanic acid-amoxicillin | 4 to 8 | 4 | 4 |
| Dibekacin | 1 to 2 | 1 | 1 |
| Flomoxef | ≤0.13 | ≤0.13 | ≤0.13 |
| Levofloxacin | ≤0.13 | ≤0.13 | ≤0.13 |
| Minocycline | 1 to 16 | 1 | 2 |
| Ofloxacin | ≤0.13 | ≤0.13 | ≤0.13 |
| Piperacillin | 0.50 to 8 | 1 | 1 |
| Sulbactam-cefoperazone | ≤0.13 to 0.25 | ≤0.13 | ≤0.13 |
| Tosufloxacin | ≤0.13 | ≤0.13 | ≤0.13 |
| Vancomycin | 64 to >128 | 128 | 128 |
| Fosfomycin | |||
| O157 | 16 to 32 | 16 | 32 |
| Non-O157 | 2 to 128 | 16 | 128 |
| Fosfomycin-G6Pb | |||
| O157 | ≤0.13 to 0.5 | 0.5 | 0.5 |
| Non-O157 | 1 to 64 | 4 | 16 |
| Kanamycin | |||
| O157 | 2 to 4 | 2 | 4 |
| Non-O157 | 2 to 64 | 4 | 32 |
| Norfloxacin | |||
| O157 | ≤0.13 | ≤0.13 | ≤0.13 |
| Non-O157 | ≤0.13 to 2 | ≤0.13 | ≤0.13 |
The data are for O157 unless indicated otherwise. 50% and 90%, concentrations of antimicrobial agents which inhibited growth in 50 and 90% of the strains, respectively.
3 μg of G6P per ml.